- FDA approves AstraZeneca’s baxdrostat for certain patients with hypertensionOne of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday. The blood ...Endpoints · 2mo ago↗ source
- Unlocking more value from mature drug products through strategic outsourcing<p>See how strategic outsourcing can maximize value and reduce costs for mature drug portfolios.</p>BioPharma Dive · 2mo ago↗ source
- <![CDATA[Dr Meeks on a Real-World Study of BCG Retreatment After BCG Failure in NMIBC]]><![CDATA[Joshua J. Meeks, MD, PhD, discusses data from a real-world study of BCG retreatment after BCG failure in NMIBC.]]>onclive · 2mo ago